MLTX NOTIFICATION: BFA Law Notifies MoonLake Immunotherapeutics Investors of the Pending Class Action Lawsuit and Upcoming December 15 Legal Deadline

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a legal deadline for investors to act by December 15, 2025 [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [5]. Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data and the advantages of SLK's Nanobody structure compared to traditional monoclonal antibody treatments, which may have misled investors regarding the drug's regulatory approval and commercial viability [6][7]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].